PMID- 2897996
OWN - NLM
STAT- MEDLINE
DCOM- 19880725
LR  - 20190709
IS  - 0022-0795 (Print)
IS  - 0022-0795 (Linking)
VI  - 117
IP  - 2
DP  - 1988 May
TI  - Involvement of the somatostatin and cholinergic systems in the mechanism of 
      growth hormone autofeedback regulation in the rat.
PG  - 273-81
AB  - The involvement of the cholinergic system in GH secretion has recently acquired 
      increasing importance. Data have been presented suggesting that in rats the 
      effect of cholinergic modulation on GH secretion takes place through inhibition 
      or stimulation of hypothalamic somatostatin (SRIF) release. To investigate 
      further the significance of cholinergic-SRIF link and its role in the regulation 
      of GH secretion, the action of cholinergic agonist and antagonist drugs in the GH 
      short-loop feedback mechanism mediated by SRIF was investigated. 
      Intracerebroventricular (i.c.v.) infusion of 0.2 or 2.0 micrograms GH/rat into 
      the lateral brain ventricle of adult male rats induced a significant reduction in 
      the GH-releasing hormone (GHRH; 2 micrograms/kg, i.v.)-induced peak GH rise, but 
      only the 2.0 micrograms dose reduced also the GH-integrated area after 
      administration of GHRH. This effect was absent after central administration of 
      20.0 micrograms GH/rat, due probably to leakage of some GH from the cerebral 
      ventricle into the systemic circulation. Pretreatment with cysteamine (300 mg/kg, 
      s.c.), a known depletor of hypothalamic SRIF, or with anti-SRIF serum (0.5 
      ml/rat) completely counteracted the lessening of the GH response to GHRH induced 
      by 2.0 micrograms GH injected i.c.v. Similarly, pretreatment with the cholinergic 
      agonist pilocarpine (3 mg/kg, i.v.) completely antagonized the inhibitory effect 
      of central infusion of GH on the GHRH-induced GH response. Atropine (1.0 mg/kg, 
      i.v.), a muscarinic cholinergic antagonist, strikingly inhibited the GHRH-induced 
      GH rise, but when given in combination with i.c.v. infusion of GH there was no 
      additive inhibitory effect.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Torsello, A
AU  - Torsello A
AD  - Department of Pharmacology, Chemotherapy and Toxicology, University of Milan, 
      Italy.
FAU - Panzeri, G
AU  - Panzeri G
FAU - Cermenati, P
AU  - Cermenati P
FAU - Caroleo, M C
AU  - Caroleo MC
FAU - Ghigo, E
AU  - Ghigo E
FAU - Camanni, F
AU  - Camanni F
FAU - Muller, E E
AU  - Muller EE
FAU - Locatelli, V
AU  - Locatelli V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Endocrinol
JT  - The Journal of endocrinology
JID - 0375363
RN  - 01MI4Q9DI3 (Pilocarpine)
RN  - 51110-01-1 (Somatostatin)
RN  - 5UX2SD1KE2 (Cysteamine)
RN  - 7C0697DR9I (Atropine)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
MH  - Animals
MH  - Atropine/*pharmacology
MH  - Cysteamine/pharmacology
MH  - Feedback
MH  - Growth Hormone/*metabolism
MH  - Hypothalamus/drug effects
MH  - Male
MH  - Pilocarpine/*pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Somatostatin/antagonists & inhibitors/*physiology
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
AID - 10.1677/joe.0.1170273 [doi]
PST - ppublish
SO  - J Endocrinol. 1988 May;117(2):273-81. doi: 10.1677/joe.0.1170273.